Purpose: To investigate whether potential differences in staging between a traditional staging imaging algorithm and F-FDG PET/MR lead to a change in patient management in breast carcinoma and to compare the diagnostic accuracy between the traditional staging algorithm and F-FDG PET/MR for the TNM classification.
Method: In this prospective cohort study from two university hospitals 56 women with newly diagnosed, therapy-naive breast cancer and increased pre-test probability for distant metastases were included. All patients were examined by a traditional staging imaging algorithm (X-ray mammography, breast ultrasonography, chest plain radiography, bone scintigraphy, and ultrasonography of the liver and axillary fossa) and whole-body F-FDG PET/MR including dedicated F-FDG PET/MR breast examinations. Each patient was discussed two times in a separate tumor board session to determine a total of three therapy recommendations based on histopathological data of the primary tumor and (1) traditional algorithm only, (2) traditional algorithm and F-FDG PET/MR, and (3) F-FDG PET/MR only. Major changes in therapy recommendations and differences between the traditional staging algorithm and F-FDG PET/MR for the TNM classification were evaluated.
Results: Staging by F-FDG PET/MR led to a difference in treatment compared the traditional staging algorithm in 8/56 cases (14%). Therapy changes included therapy of the breast, locoregional nodes and systemic therapy. A trend to staging superiority was found for F-FDG PET/MRI without statistical significance (p = 0.3827).
Conclusion: In conclusion, for breast cancer patients with elevated pre-test probability for distant metastases a change of the therapy regiment occurs in 14 % of patients when staged by F-FDG PET/MR and confirmed by histopathology compared to a traditional staging algorithm. In particular with regard to the amendment of the guideline further assessment of F-FDG-PET/MR in this setting is necessary to assess the true value of this modality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587896 | PMC |
| http://dx.doi.org/10.1016/j.ejrad.2020.108975 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of Crossed Cerebellar Diaschisis in Intractable Epilepsy Using Integrated F-FDG PET/MR Imaging.
Cerebellum
December 2024
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Crossed cerebellar diaschisis(CCD) involves reduced metabolism and blood flow in the cerebellar hemisphere contralateral to a supratentorial lesion. ASL is a valuable tool for quantifying regional cerebral blood flow. This study assesses ASL-MRI's ability to detect CCD in epilepsy using integrated F-FDG PET/MRI and compares ASL with PET images in evaluating CCD.
View Article and Find Full Text PDFCasticin inhibits proliferation of Non-small cell lung cancer cells through regulating reprogramming of glucose metabolism.
Phytomedicine
November 2024
Department of nuclear medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, PR China. Electronic address:
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with poor prognosis due to its rapid progression and resistance to existing therapies. Metabolic reprogramming, particularly alterations in glucose metabolism, is a key mechanism underlying tumor growth and progression, providing potential targets for novel therapeutic strategies. Casticin (CAS), a bioactive flavonoid, has shown anticancer effects in various cancers, but its specific role in NSCLC metabolism remains unclear.
View Article and Find Full Text PDFPositron emission tomography-magnetic resonance imaging applications in pediatric musculoskeletal tumors.
Quant Imaging Med Surg
November 2024
Radiology Unit, Alcorcon Foundation University Hospital, Alcorcon, Madrid, Spain.
Background: The hybrid imaging positron emission tomography/magnetic resonance (PET/MR) is an important tool in the management of pediatric oncology patients, particularly in malignant musculoskeletal pathologies, because it combines the functional and metabolic information of tumor provided by PET with the high soft-tissue contrast and the functional information offered by magnetic resonance imaging (MRI).
Methods: We performed an observational retrospective study that included pediatric patients diagnosed with primary bone or soft-tissue sarcomas in the Pediatric Hematology and Oncology Unit at the HM Montepríncipe University Hospital, Boadilla del Monte, Madrid (Spain) who underwent whole-body F-fluorodeoxyglucose (F-FDG) PET/MRI as a staging study and for follow-up evaluation for treatment response from September 2017 to January 2023. This study explores the protocols, the practical application of the PET/MRI technique and our clinical experience at our center in the diagnosis and follow-up of primary bone tumors and soft-tissue sarcomas in children.
Assessing the intracranial metabolic score as a novel prognostic tool in primary CNS lymphoma with end of induction-chemotherapy F-FDG PET/CT and PET/MR.
Cancer Imaging
November 2024
Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Article Synopsis
- This study investigates the prognostic value of a new scoring system called the intracranial metabolic score (IMS) in patients with primary central nervous system lymphoma (PCNSL) who undergo end-of-therapy imaging using F-FDG PET/CT and PET/MR.
- The IMS is based on the metabolism of normal brain structures and was shown to outperform the traditional Deauville score (DS) in predicting progression-free survival (PFS) and overall survival (OS).
- Results from the study suggest that a higher IMS score is associated with worse patient outcomes, confirming the IMS as a valuable prognostic tool for assessing PCNSL treatment effectiveness.
Preoperative assessment of pancreatic cancer with [Ga]Ga-DOTA-FAPI-04 PET/MR versus [F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.
Purpose: To assess the diagnostic performance of [Ga]Ga-DOTA-FAPI-04 PET/MR imaging in the preoperative evaluation of pancreatic cancer and compare it with that of [F]-FDG PET/CT plus contrast-enhanced CT (CECT).
Methods: Thirty-one patients with pancreatic cancer underwent preoperative [Ga]Ga-DOTA-FAPI-04 PET/MR, [F]-FDG PET/CT, and CECT imaging. Two nuclear medicine physicians independently reviewed two sets of images (set 1, [Ga]Ga-DOTA-FAPI-04 PET/MR; set 2, [F]-FDG PET/CT plus CECT) and reached a consensus on tumour resectability, N staging (N0 or N positive) and M staging (M0 or M1).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!